CAR T-cells (anti-CD19)

CAR T-cells (anti-CD19) refers to chimeric antigen receptor (CAR) T-cell therapies engineered to target the CD19 antigen, which is highly expressed on the surface of B-lineage cells. This therapeutic modality involves isolating a patient's (or donor's) T cells, genetically modifying them ex vivo to express a CAR specific to CD19, expanding them, and infusing them back into the patient. Upon binding to CD19 on target cells (such as malignant or autoreactive B cells), the CAR T-cells are activated, leading to targeted cytotoxicity, proliferation, and cytokine release. This platform has revolutionized the treatment of B-cell malignancies, including B-cell precursor acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia (CLL). Additionally, anti-CD19 CAR T-cells are being actively investigated for the treatment of severe, refractory B-cell-mediated autoimmune diseases, such as systemic lupus erythematosus (SLE), systemic sclerosis, and myasthenia gravis.

Other names

CD19 CAR-T cellsCD-19 CAR-T cellsCD 19 CAR-T cellsCD19-directed CAR-T cell therapyCD-19-directed CAR-T cell therapyCD 19-directed CAR-T cell therapyCD19-directed CAR-T cellsCD-19-directed CAR-T cellsCD 19-directed CAR-T cellsCD19-targeted CAR-T cell therapyCD-19-targeted CAR-T cell therapyCD 19-targeted CAR-T cell therapyCD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cellsanti-CD19 CAR T-cellsanti-CD-19 CAR T-cellsanti-CD 19 CAR T-cellsanti-CD19 CAR-T cell therapyanti-CD-19 CAR-T cell therapyanti-CD 19 CAR-T cell therapyanti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cells